{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T17:10:15Z","timestamp":1778433015597,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Glucocorticoid-induced osteoporosis (GIOP) is one of the most frequent causes of secondary osteoporosis, especially in young subjects. However, current research and guidelines have scarcely addressed the therapeutic approach and risk factors for GIOP in adults less than 50 years of age. The aim of the study was to analyze if factors related to the development of glucocorticoid-induced osteoporosis (GIOP) and fragility fractures (FF) differ according to age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>127 patients on chronic glucocorticoid (GC) treatment were analyzed, including GC doses and duration, disease activity, FF, anthropometric data, bone metabolism parameters (including sex steroids), bone mineral density, trabecular bone score, and radiologic vertebral fractures; defining GIOP as densitometric osteoporosis and\/or FF. Young subjects (&amp;lt;50 years old) were compared with those \u226550 years for risk factors of GIOP and FF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>GIOP prevalence was similar in both age groups: &amp;lt;50 (n=36) 44.4% <jats:italic>vs.<\/jats:italic> 46.1% \u226550 years (n=91). Five subjects &amp;lt;50 (13.9%) and 30 \u226550 years (33%) presented FF (p=0.046). Having a higher body mass index (BMI), disease activity was a differential risk factor for FF in young subjects, whereas hypogonadism was a risk factor independent of age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>More than 40% of young subjects on chronic GC therapy had GIOP. A higher BMI and disease activity and particularly, hypogonadism seem to be factors related to FF development in these subjects. Evaluation of these risk factors can improve the identification of young subjects at increased risk of fracture.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1528962","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T04:10:36Z","timestamp":1752207036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk factors for glucocorticoid induced osteoporosis in young adults"],"prefix":"10.3389","volume":"16","author":[{"given":"Helena","family":"Florez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Lluis","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Barber\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Africa","family":"Muxi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Mocritcaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Prieto-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Monegal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Gua\u00f1abens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Peris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ajog.2005.08.047","article-title":"Epidemiology, etiology, and diagnosis of osteoporosis","volume":"194","author":"Lane","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14637","article-title":"Challenges in the diagnosis and management of glucocorticoid-induced osteoporosis in younger and older adults","volume":"96","author":"Herath","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1578","article-title":"Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases","volume":"94","author":"Tatsuno","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bonr.2016.11.003","article-title":"Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study","volume":"6","author":"Kageyama","year":"2016","journal-title":"Bone Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3523","article-title":"Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions","volume":"33","author":"Balasubramanian","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4443","article-title":"Age, initial dose and dose increase are independent risk factors for symptomatic vertebral fractures in glucocorticoid-treated male patients","volume":"50","author":"Sugiyama","year":"2011","journal-title":"Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2645","article-title":"Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008)","volume":"97","author":"Majumdar","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2154oa","article-title":"High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients","volume":"14","author":"Borba","year":"2005","journal-title":"Lupus"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.20568","article-title":"Osteoporosis and fractures in systemic lupus erythematosus","volume":"64","author":"Bultink","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/art.40137","article-title":"2017 american college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001355","article-title":"Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses","volume":"6","author":"Florez","year":"2020","journal-title":"RMD Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez464","article-title":"Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis","volume":"59","author":"Florez","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4321\/S1889-836X2022000100003","article-title":"Clinical practice guidelines for postmenopausal, glucocorticoid-induced and male osteoporosis: 2022 update. Spanish Society for Bone and Mineral Metabolism Research (SEIOMM)","volume":"14","author":"Riancho","year":"2022","journal-title":"Rev Osteoporos Metab Miner"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01502-w","article-title":"The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis","volume":"42","author":"Tanaka","year":"2024","journal-title":"J Bone Miner Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-022-02261-2","article-title":"Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update: This manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF)","volume":"34","author":"Messina","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","volume":"23","author":"Lekamwasam","year":"2012","journal-title":"Osteoporos Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/jcm8020209","article-title":"The optimal indication for testosterone replacement therapy in late onset hypogonadism","volume":"8","author":"Shin","year":"2019","journal-title":"J Clin Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0124","article-title":"Official positions of the international society for clinical densitometry","volume":"89","author":"Lewiecki","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.08.106","article-title":"International Society for Clinical Densitometry 2007 adult and pediatric official positions","volume":"43","author":"Lewiecki","year":"2008","journal-title":"Bone"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-013-0161-4","article-title":"Evaluation and management of the premenopausal woman with low BMD","volume":"11","author":"Cohen","year":"2013","journal-title":"Curr Osteoporos Rep"},{"key":"B21","unstructured":"Vienna, Austria\n          R Foundation for Statistical Computing\n          R: A language and environment for statistical computing\n          \n          2022"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3078-1","article-title":"The impact of glucocorticoid therapy on trabecular bone score in older women","volume":"26","author":"Paggiosi","year":"2015","journal-title":"Osteoporos Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008661","article-title":"Trabecular bone score as a supplementary tool for the discrimination of osteoporotic fractures in postmenopausal women with rheumatoid arthritis","volume":"96","author":"Choi","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000014","article-title":"Glucocorticoid-induced osteoporosis","volume":"1","author":"Briot","year":"2015","journal-title":"RMD Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.42529","article-title":"Bone loss in inflammatory rheumatic musculoskeletal disease patients treated with low-dose glucocorticoids and prevention by anti-osteoporosis medications","volume":"75","author":"Adami","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbrc.2010.02.113","article-title":"Further evidence for direct pro-resorptive actions of FSH","volume":"394","author":"Sun","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.908727","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the belgian bone club","volume":"13","author":"Laurent","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.genm.2010.06.004","article-title":"Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid","volume":"7","author":"Sugiyama","year":"2010","journal-title":"Gend Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4189-7","article-title":"Inflammatory diseases and bone fragility","volume":"28","author":"Briot","year":"2017","journal-title":"Osteoporos Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01120-w","article-title":"Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases","volume":"20","author":"Buttgereit","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"116958","DOI":"10.1016\/j.bone.2023.116958","article-title":"Risk of fracture in women with glucocorticoid requiring diseases is independent from glucocorticoid use: An analysis on a nation-wide database","volume":"179","author":"Adami","year":"2024","journal-title":"Bone"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07397-1","article-title":"Rheumatoid arthritis and subsequent fracture risk: an individual person meta-analysis to update FRAX","volume":"36","author":"Kanis","year":"2025","journal-title":"Osteoporos Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.733611","article-title":"Endogenous glucocorticoid metabolism in bone: friend or foe","volume":"12","author":"Martin","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.06.004","article-title":"Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases","volume":"32","author":"Kumagai","year":"2005","journal-title":"J Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23879","article-title":"How do glucocorticoids used in rheumatic disease affect body weight? A narrative review of the evidence","volume":"72","author":"Morgan","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.cmet.2021.06.004","article-title":"Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids","volume":"33","author":"Hu","year":"2021","journal-title":"Cell Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1528962\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T04:10:37Z","timestamp":1752207037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1528962\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":36,"alternative-id":["10.3389\/fendo.2025.1528962"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1528962","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"article-number":"1528962"}}